Your Health, We Care
Release date: 2024-08-28 15:30:16 Recommended: 138
Balversa is specifically designed for patients with advanced urothelial carcinoma, targeting patients with FGFR mutations and bringing new hope to patients by inhibiting cancer cell growth signals, but it is necessary to pay attention to its potential side effects.
Possible interactions with other medications include:
Balversa is mainly metabolized by CYP3A4 enzymes, and when combined with CYP3A4 inhibitors (such as clarithromycin), it may reduce its metabolic rate, increase blood concentration, and increase the risk of adverse reactions; When combined with CYP3A4 inducers (e.g., rifampicin), it may accelerate its metabolism and reduce its efficacy.
Balversa may affect the metabolic function of the liver, which in turn interferes with the metabolism of anticoagulant drugs, resulting in abnormal coagulation function. When used in combination with anticoagulants such as warfarin, coagulation markers should be closely monitored to prevent bleeding events.
When discussing the treatment of Balversa, it is important to pay attention to its interaction with other drugs. In particular, when used in combination with anticoagulant drugs, it may increase the risk of bleeding, and the clinical manifestations are bleeding tendency, hematoma, etc., so it should be used with caution.
Clinical manifestations of possible interactions with Balversa in combination with anticoagulants include:
Because the anticoagulant drug itself has the effect of inhibiting blood clotting, the combination with Balversa may further enhance this effect, resulting in bleeding tendencies such as gingival bleeding, subcutaneous ecchymosis, and nosebleeds, and in severe cases, visceral hemorrhage or cerebral hemorrhage may occur.
The combination may interfere with the normal coagulation mechanism and lead to abnormal coagulation test results, such as prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), suggesting that patients are at risk of coagulation disorders.
In view of the risk of bleeding that may result from the combination of Balversa with anticoagulants, patients should pay close attention to clinical manifestations such as bleeding tendency. As soon as you notice an abnormality, you should seek medical attention immediately and inform your doctor of all medications you are taking so that you can adjust your treatment plan.
Responses to the interaction of Balversa in combination with anticoagulants include:
Coagulation indicators such as prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count is regularly measured, and abnormal coagulation function is detected in time and the dose of anticoagulant drugs is adjusted or stopped.
According to the results of coagulation monitoring, the dose of Balversa or anticoagulant drugs should be adjusted after communicating with the doctor to reduce the effects of interactions. If the dose is not effective, a change in anticoagulant or a different antineoplastic regimen may be considered.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
